Cepheid, a medical diagnostics company, recently received de novo authorization from the U.S. Food and Drug Administration (FDA) for a groundbreaking molecular test designed to detect hepatitis C virus RNA directly from fingerstick blood samples. This marks the first test of its kind in the United States, uniquely positioning it at the forefront of hepatitis C diagnostics at the point of care. This new test streamlines the diagnostic process, allowing healthcare professionals to diagnose and potentially treat hepatitis C during a single healthcare visit.
The test, approved under special controls set by Cepheid’s authorization, now paves the way for other companies to introduce similar hepatitis C tests in the U.S. market through the 510(k) pathway. This regulatory channel simplifies the approval process for new devices that are substantially equivalent to an already legally marketed device.
Hepatitis C is a liver infection caused by the hepatitis C virus, primarily spread through contaminated blood. Since 2013, treatments — notably Gilead Sciences’ Sovaldi — have become widely effective, with subsequent products achieving cure rates between 94% and 99%. Despite these advancements in treatment, the incidence of acute hepatitis C in the U.S. has more than doubled from 2014 to 2021. A significant factor in this increase has been attributed to the challenges associated with testing.
Prior to Cepheid’s recent regulatory authorization, testing for hepatitis C was a cumbersome process conducted at centralized labs which required multiple steps and follow-up visits that delayed diagnosis and treatment. Cepheid’s Xpert HCV test, performed on their Genexpert Xpress System, offers a significant improvement by reducing testing and diagnosis to approximately one hour. This rapid turnaround is expected to decrease the likelihood that individuals drop out of care before receiving a diagnosis or starting treatment.
The FDA envisions that Cepheid’s test will be particularly useful in areas where hepatitis C is most prevalent and where immediate diagnosis and treatment are critical. Advocates suggest the test could be effectively deployed in substance use disorder treatment sites, correctional facilities, and syringe service programs, considering most new infections in the U.S. occur among individuals who share needles or other drug-injection apparatus. These settings often face challenges in getting at-risk populations tested and treated due to the need for swift and comprehensive care delivery.
Jeff Shuren, director of the FDA’s Center for Device and Radiological Health, emphasized the potential community and public health impact of the test, highlighting that it enables healthcare providers to diagnose and treat patients in a single visit. This could significantly increase the number of patients diagnosed and treated for hepatitis C, thereby preventing disease progression and curbing further spread of the virus.
This advance represents a crucial development in the public health approach to managing hepatitis C, a disease which has seen persistent challenges in diagnosis and treatment despite the availability of effective therapies. With the introduction of Cepelope’s rapid molecular test, the healthcare community anticipates broader access to vital diagnostic services, particularly for populations that are difficult to reach and treat under traditional healthcare models. This move by the FDA and Cepheid could potentially transform the landscape of hepatitis C management, contributing to more effective control and potentially the eradication of the disease in targeted settings.
#Cepheid #wins #FDA #nod #fingerstick #hepatitis #test
